Education
About Us
Working with TipRanks
Follow Us
PYC Therapeutics Limited (AU:PYC)
ASX:PYC
RESEARCH TOOLSreports
Total Valuation
PYC Therapeutics Limited has a market cap or net worth of AU$729.08M. The enterprise value is AU$424.89M.
Market CapAU$729.08M
Enterprise ValueAU$424.89M
Share Statistics
PYC Therapeutics Limited has 583,260,440 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding583,260,440
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
PYC Therapeutics Limited’s return on equity (ROE) is -0.47 and return on invested capital (ROIC) is -32.27%.
Return on Equity (ROE)-0.47
Return on Assets (ROA)-0.41
Return on Invested Capital (ROIC)-32.27%
Return on Capital Employed (ROCE)-0.47
Revenue Per Employee959.10K
Profits Per Employee-1.64M
Employee Count23
Asset Turnover0.24
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of PYC Therapeutics Limited is -123.96. PYC Therapeutics Limited’s PEG ratio is -3.34.
PE Ratio-123.96
PS Ratio0.00
PB Ratio58.09
Price to Fair Value58.09
Price to FCF-120.23
Price to Operating Cash Flow-121.19
PEG Ratio-3.34
Income Statement
In the last 12 months, PYC Therapeutics Limited had revenue of 22.06M and earned -37.73M in profits. Earnings per share was -0.01.
Revenue22.06M
Gross Profit22.06M
Operating Income-38.86M
Pretax Income-55.67M
Net Income-37.73M
EBITDA-38.12M
Earnings Per Share (EPS)-0.01
Cash Flow
In the last 12 months, operating cash flow was -48.77M and capital expenditures -780.06K, giving a free cash flow of -49.55M billion.
Operating Cash Flow-48.77M
Free Cash Flow-49.55M
Free Cash Flow per Share-0.08
Dividends & Yields
PYC Therapeutics Limited pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.62
52-Week Price Change32.98%
50-Day Moving Average1.18
200-Day Moving Average1.38
Relative Strength Index (RSI)56.40
Average Volume (3m)579.87K
Important Dates
PYC Therapeutics Limited upcoming earnings date is Sep 2, 2025, TBA Not Confirmed.
Last Earnings DateFeb 27, 2025
Next Earnings DateSep 2, 2025
Ex-Dividend Date―
Financial Position
PYC Therapeutics Limited as a current ratio of 9.40, with Debt / Equity ratio of 2.18%
Current Ratio9.40
Quick Ratio9.40
Debt to Market Cap0.00
Net Debt to EBITDA1.73
Interest Coverage Ratio-789.64
Taxes
In the past 12 months, PYC Therapeutics Limited has paid -17.56M in taxes.
Income Tax-17.56M
Effective Tax Rate0.32
Enterprise Valuation
PYC Therapeutics Limited EV to EBITDA ratio is -120.96, with an EV/FCF ratio of -118.54.
EV to Sales209.01
EV to EBITDA-120.96
EV to Free Cash Flow-118.54
EV to Operating Cash Flow-119.48
Balance Sheet
PYC Therapeutics Limited has AU$49.25M in cash and marketable securities with AU$1.21M in debt, giving a net cash position of -AU$48.04M billion.
Cash & Marketable SecuritiesAU$49.25M
Total DebtAU$1.21M
Net Cash-AU$48.04M
Net Cash Per Share-AU$0.08
Tangible Book Value Per ShareAU$0.02
Margins
Gross margin is 100.00%, with operating margin of -176.15%, and net profit margin of -171.02%.
Gross Margin100.00%
Operating Margin-176.15%
Pretax Margin-252.36%
Net Profit Margin-171.02%
EBITDA Margin-172.80%
EBIT Margin-176.15%
Analyst Forecast
The average price target for PYC Therapeutics Limited is AU$3.14, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price TargetAU$3.14
Price Target Upside151.20% Upside
Analyst ConsensusStrong Buy
Analyst Count5
Revenue Growth Forecast―
EPS Growth Forecast-84.82%